ZL-6201

ZL-6201 is an investigational antibody-drug conjugate (ADC) being developed for the treatment of multiple solid tumors. It targets leucine-rich repeat-containing protein 15 (LRRC15), a type I transmembrane protein that is overexpressed in various mesenchymal tumors such as sarcoma, glioblastoma, and melanoma. LRRC15 is also upregulated in cancer-associated fibroblasts across several cancer types, contributing to tumor metastasis and creating an immune-suppressive tumor microenvironment. By targeting LRRC15, ZL-6201 aims to disrupt these processes and provide a novel therapeutic approach for solid tumors. The drug utilizes MediLink Therapeutics' TMALIN ADC platform technology combined with an antibody discovered by Zai Lab. As of early 2025, ZL-6201 has demonstrated promising preclinical data with an Investigational New Drug (IND) application expected to be filed in 2025.